Safety, immunogenicity and pharmacokinetics (PK) of a 120 mg/kg/week dose of alpha1 -proteinase inhibitor in alpha1 -antitrypsin deficiency Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
SPARTA: Efficacy and safety assessment of two regimens of alpha1 -proteinase inhibitor in emphysema due to alpha1 -antitrypsin deficiency Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Determination of T1/2 (half-lives) plasmatic of HIN, a possible distinction method of the patients that present secondary effects at the therapy with tuberculostatics Source: Eur Respir J 2005; 26: Suppl. 49, 428s Year: 2005
Interrelationship of pharmacokinetics/pharmacodynamics: antibiotic dosing for the future Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=1 Year: 2004
Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency Source: Annual Congress 2010 - COPD: phenotyping and monitoring Year: 2010
Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma Source: Eur Respir J 2006; 28: 1042-1050 Year: 2006
Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
Population pharmacokinetics of A1-PI in patients with Alpha-1 antitrypsin deficiency Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Assessment of A1-PI dose-exposure and exposure-response relationships in patients with Alpha-1 antitrypsin inhibitor deficiency Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Effect of intravenous alpha-1-antitrypsin augmentation therapy on proteinase-3-generated AaVal541 in deficient patients Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Effects of biweekly Alpha1 antitrypsin replacement therapy: a case series Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD Year: 2020
LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV568, a narrow spectrum kinase inhibitor, following repeat inhaled dosing in COPD patients Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
Therapeutic efficacy of alpha-1 antitrypsin (AAT) augmentation therapy on the loss of lung tissue: an integrated analysis Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008
Homecare setting of longterm augmentation therapy in alpha1 antitrypsin defiency patients leads to clinical stabilization Source: International Congress 2017 – New frontiers in home care management of chronic lung diseases Year: 2017
Late Breaking Abstract - PK/PD assessment of an oral, selective aVß6/aVß1 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
Pulmonary administration of alpha1 -antitrypsin for the treatment of Alpha1 -antitrypsin deficiency Source: Eur Respir J 2003; 22: Suppl. 45, 385s Year: 2003
Pilot study for detection of alpha-1 antitrypsin deficiency in a targeted Argentinean population Source: Eur Respir J 2005; 26: Suppl. 49, 59s Year: 2005
Genotyping and phenotyping of alpha1-antitrypsin deficiency Greek patients under augmentation therapy: a multicenter study Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling Year: 2020
Efficacy of augmentation therapy for emphysema associated with alpha1-antitrypsin deficiency: enough is enough Source: Eur Respir J 2016; 47: 35-38 Year: 2016